Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Eur J Cancer
; 131: 27-36, 2020 05.
Article
in En
| MEDLINE
| ID: mdl-32276179
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Paclitaxel
/
Carcinoma, Non-Small-Cell Lung
/
Bevacizumab
/
Docetaxel
/
Lung Neoplasms
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eur J Cancer
Year:
2020
Document type:
Article
Country of publication: